Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper.
Authors
Caroli, Anna
Schneider, Moritz
Friedli, Iris
Ljimani, Alexandra
De Seigneux, Sophie
Boor, Peter
Gullapudi, Latha
Kazmi, Isma
Mendichovszky, Iosif A
Notohamiprodjo, Mike
Selby, Nicholas M
Thoeny, Harriet C
Grenier, Nicolas
Vallée, Jean-Paul
Publication Date
2018-09-01Journal Title
Nephrol Dial Transplant
ISSN
0931-0509
Publisher
Oxford University Press (OUP)
Volume
33
Issue
suppl_2
Pages
ii29-ii40
Language
eng
Type
Article
Physical Medium
Print
Metadata
Show full item recordCitation
Caroli, A., Schneider, M., Friedli, I., Ljimani, A., De Seigneux, S., Boor, P., Gullapudi, L., et al. (2018). Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper.. Nephrol Dial Transplant, 33 (suppl_2), ii29-ii40. https://doi.org/10.1093/ndt/gfy163
Abstract
Diffusion-weighted magnetic resonance imaging (DWI) is a non-invasive method sensitive to local water motion in the tissue. As a tool to probe the microstructure, including the presence and potentially the degree of renal fibrosis, DWI has the potential to become an effective imaging biomarker. The aim of this review is to discuss the current status of renal DWI in diffuse renal diseases. DWI biomarkers can be classified in the following three main categories: (i) the apparent diffusion coefficient-an overall measure of water diffusion and microcirculation in the tissue; (ii) true diffusion, pseudodiffusion and flowing fraction-providing separate information on diffusion and perfusion or tubular flow; and (iii) fractional anisotropy-measuring the microstructural orientation. An overview of human studies applying renal DWI in diffuse pathologies is given, demonstrating not only the feasibility and intra-study reproducibility of DWI but also highlighting the need for standardization of methods, additional validation and qualification. The current and future role of renal DWI in clinical practice is reviewed, emphasizing its potential as a surrogate and monitoring biomarker for interstitial fibrosis in chronic kidney disease, as well as a surrogate biomarker for the inflammation in acute kidney diseases that may impact patient selection for renal biopsy in acute graft rejection. As part of the international COST (European Cooperation in Science and Technology) action PARENCHIMA (Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease), aimed at eliminating the barriers to the clinical use of functional renal magnetic resonance imaging, this article provides practical recommendations for future design of clinical studies and the use of renal DWI in clinical practice.
Keywords
Kidney, Humans, Diffusion Magnetic Resonance Imaging, Renal Insufficiency, Chronic, Practice Guidelines as Topic, Biomarkers
Sponsorship
EU COST Programme
Embargo Lift Date
2100-01-01
Identifiers
External DOI: https://doi.org/10.1093/ndt/gfy163
This record's URL: https://www.repository.cam.ac.uk/handle/1810/280557
Rights
Attribution-NonCommercial 4.0 International
Licence URL: http://creativecommons.org/licenses/by-nc/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.